ORIGINAL ARTICLE

Saxagliptin alters bile acid profiles and yields metabolic benefits in drug-naïve overweight or obese type 2 diabetes patient^†

超重或肥胖的初治2型糖尿病患者服用沙格列汀后胆汁酸组分的改变及代谢获益

Wen Li

Department of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao-Tong University, School of Medicine, Shanghai Key Laboratory for Endocrine Tumours, Shanghai Clinical Centre for Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases and Shanghai Institute for Endocrinology, Shanghai, China

Search for more papers by this author

Ruixin Liu,

Ruixin Liu

Search for more papers by this author

Xuelin Li,

Xuelin Li

Search for more papers by this author

Bei Tao,

Bei Tao

Search for more papers by this author

Nan Zhai,

Nan Zhai

Search for more papers by this author

Xiaolin Wang,

Xiaolin Wang

Chinese Academy of Sciences Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Science, Dalian, China

Search for more papers by this author

Qi Li,

Qi Li

Chinese Academy of Sciences Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Science, Dalian, China

Search for more papers by this author

Yifei Zhang,

Yifei Zhang

Search for more papers by this author

Weiqiong Gu,

Weiqiong Gu

orcid.org/0000-0002-3296-3384

Search for more papers by this author

Weiqing Wang,

Corresponding Author

Weiqing Wang

[email protected]

Correspondence

Weiqing Wang, Shanghai Ruijin Hospital, No. 197, Ruijin Er Road, Shanghai 200025, PR China.

Email: [email protected]

Search for more papers by this author

Guang Ning,

Guang Ning

Laboratory of Endocrinology and Metabolism, Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences and Shanghai Jiao Tong University School of Medicine, Shanghai, China

Search for more papers by this author

Wen Li,

Wen Li

Search for more papers by this author

Ruixin Liu,

Ruixin Liu

Search for more papers by this author

Xuelin Li,

Xuelin Li

Search for more papers by this author

Bei Tao,

Bei Tao

Search for more papers by this author

Nan Zhai,

Nan Zhai

Search for more papers by this author

Xiaolin Wang,

Xiaolin Wang

Chinese Academy of Sciences Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Science, Dalian, China

Search for more papers by this author

Qi Li,

Qi Li

Chinese Academy of Sciences Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Science, Dalian, China

Search for more papers by this author

Yifei Zhang,

Yifei Zhang

Search for more papers by this author

Weiqiong Gu,

Weiqiong Gu

orcid.org/0000-0002-3296-3384

Search for more papers by this author

Weiqing Wang,

Corresponding Author

Weiqing Wang

[email protected]

Correspondence

Weiqing Wang, Shanghai Ruijin Hospital, No. 197, Ruijin Er Road, Shanghai 200025, PR China.

Email: [email protected]

Search for more papers by this author

Guang Ning,

Guang Ning

Search for more papers by this author

First published: 29 May 2019

https://doi.org/10.1111/1753-0407.12956

Citations: 15

^†

This study is registered with Clinicaltrials.gov (ID: NCT01768208).

^‡

Wen Li, Ruixin Liu and Xuelin Li contributed equally to this work.

^§

All decisions regarding this paper, coauthored by the Editor-in-Chief, were made by Guang Ning.

^¶

Funding information: This study was supported by grants from the National Key R&D Program of China, Grant/Award Number: 2018YFC1314800; Chinese National Natural Science Foundation, Grant/Award Number: 81730023; Shanghai Municipal Education Commission – Gaofeng Clinical Medicine Grant Support, Grant/Award Number: 20161403

Share a link

Email
Wechat
Bluesky

Abstract

Background

The aim of the present study was to investigate the metabolic benefits of saxagliptin and its effects on serum bile acids (BAs) in normal weight and overweight/obese drug-naïve type 2 diabetes (T2D) patients.

Methods

In all, 282 drug-naïve T2D patients (123 normal weight [NW], with body mass index [BMI] between 19.0 and <25.0 kg/m²; 159 overweight/obese [OW/OB], with BMI ≥25.0 kg/m²) were enrolled in the study and treated with saxagliptin 5 mg daily for 24 weeks. Serum BAs were assayed by liquid chromatography with tandem mass spectrometry.

Results

At 24 weeks, HbA1c was significantly reduced in both groups, but the HbA1c levels were lower in the OW/OB than NW group. Moreover, significant decreases were seen at 24 weeks in C-reactive protein (CRP), aspartate aminotransferase, alanine aminotransferase, waist circumference, and systolic blood pressure in the OW/OB group. Interestingly, cholic acid, glycocholic acid, glycochenodeoxycholic acid, glycodeoxycholic acid (GDCA), and glycoursodeoxycholic acid (GUDCA) were increased in both groups after treatment, whereas chenodeoxycholic acid and deoxycholic acid (DCA) were specifically increased in the OW/OB group. Increased DCA and GDCA concentrations were significantly associated with decreased HbA1c or fasting blood glucose and CRP levels, whereas increased GDCA and GUDCA concentrations were associated with decreased waist circumference in the OW/OB group during treatment. In the NW group, increased GUDCA concentrations were significantly associated with a decrease in HbA1c.

Conclusions

Type 2 diabetes patients with OW/OB exhibited greater improvement in glycemic control and additional metabolic benefits after saxagliptin treatment. Saxagliptin significantly increased the BA pool, and DCA and GDCA were associated with metabolic improvements in OW/OB T2D patients.

摘要

背景

本研究旨在探究正常体重和超重/肥胖的初治2型糖尿病患者服用沙格列汀之后, 其代谢获益以及对血清胆汁酸的影响。

方法

本研究募集了282例初治2型糖尿病患者, 根据治疗前的体质指数(body mass index, BMI)分为正常体重组(NW, 19.0<BMI<25.0 kg/m², n=123)和超重/肥胖组(OW/OB, BMI≥25.0 kg/m², n=159), 分别接受为期24周, 每天5 mg的沙格列汀治疗, 并使用液相色谱-串联质谱法检测患者血清中的胆汁酸组分。

结果

使用沙格列汀24周后, 两组的糖化血红蛋白(HbA1c)均显著下降, 但OW/OB组患者的HbA1c比NW组下降得更加显著。此外, 在OW/OB组还观察到C-反应蛋白(CRP)、天冬氨酸氨基转移酶、丙氨酸氨基转移酶、腰围和收缩压显著下降。两组患者血清中的胆酸(CA)、甘氨胆酸(GCA)、甘氨鹅脱氧胆酸(GCDCA)、甘氨脱氧胆酸(GDCA)和甘氨熊脱氧胆酸(GUDCA)在用药24周之后均升高, 而鹅脱氧胆酸(CDCA)和脱氧胆酸(DCA)只在OW/OB组患者的血清中升高。在服药过程中, OW/OB组患者血清中DCA和GDCA水平的上升与其空腹血糖以及CRP的下降有显著相关性, 而GDCA和GUDCA水平的上升与腰围的下降有显著的相关性。在NW组患者中可观察到GUDCA的上升与HbA1c的下降有显著相关性。

结论

肥胖/超重的2型糖尿病患者服用沙格列汀之后的血糖控制以及代谢获益更多。沙格列汀可以有效扩大胆汁酸池, 其中DCA和GDCA与肥胖/超重2型糖尿病患者用药后的代谢改善密切相关。

Supporting Information

REFERENCES

1Wang L, Gao P, Zhang M, et al. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013. JAMA. 2017; 317: 2515-2523.
10.1001/jama.2017.7596
PubMed Web of Science® Google Scholar
2Xu Y, Wang L, He J, Bi Y, Li M. Prevalence and control of diabetes in Chinese adults. JAMA. 2013; 310: 948-959.
10.1001/jama.2013.168118
CAS PubMed Web of Science® Google Scholar
3Men P, Li XT, Tang HL, Zhai SD. Efficacy and safety of saxagliptin in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS One. 2018; 13:e0197321.
10.1371/journal.pone.0197321
PubMed Web of Science® Google Scholar
4Wu D, Li L, Liu C. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes Obes Metab. 2014; 16: 30-37.
10.1111/dom.12174
CAS PubMed Web of Science® Google Scholar
5Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2014; 63: 2985-3023.
10.1016/j.jacc.2013.11.004
PubMed Web of Science® Google Scholar
6Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006; 368: 1696-1705.
10.1016/S0140-6736(06)69705-5
CAS PubMed Web of Science® Google Scholar
7Schaap FG, Trauner M, Jansen PL. Bile acid receptors as targets for drug development. Nat Rev Gastroenterol Hepatol. 2014; 11: 55-67.
10.1038/nrgastro.2013.151
CAS PubMed Web of Science® Google Scholar
8de Aguiar Vallim TQ, Tarling EJ, Edwards PA. Pleiotropic roles of bile acids in metabolism. Cell Metab. 2013; 17: 657-669.
10.1016/j.cmet.2013.03.013
CAS PubMed Web of Science® Google Scholar
9Prawitt J, Caron S, Staels B. Bile acid metabolism and the pathogenesis of type 2 diabetes. Curr Diab Rep. 2011; 11: 160-166.
10.1007/s11892-011-0187-x
CAS PubMed Web of Science® Google Scholar
10Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K. Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov. 2008; 7: 678-693.
10.1038/nrd2619
CAS PubMed Web of Science® Google Scholar
11Rajani C, Jia W. Bile acids and their effects on diabetes. Front Med. 2018; 12: 608-623.
10.1007/s11684-018-0644-x
PubMed Web of Science® Google Scholar
12Makishima M, Okamoto AY, Repa JJ, et al. Identification of a nuclear receptor for bile acids. Science. 1999; 284: 1362-1365.
10.1126/science.284.5418.1362
CAS PubMed Web of Science® Google Scholar
13Parks DJ, Blanchard SG, Bledsoe RK, et al. Bile acids: natural ligands for an orphan nuclear receptor. Science. 1999; 284: 1365-1368.
10.1126/science.284.5418.1365
CAS PubMed Web of Science® Google Scholar
14Pols TW, Noriega LG, Nomura M, Auwerx J, Schoonjans K. The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation. J Hepatol. 2011; 54: 1263-1272.
10.1016/j.jhep.2010.12.004
CAS PubMed Web of Science® Google Scholar
15Jiang C, Xie C, Lv Y, et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat Commun. 2015; 6: 10166.
10.1038/ncomms10166
CAS PubMed Web of Science® Google Scholar
16Li F, Jiang C, Krausz KW, et al. Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat Commun. 2013; 4: 2384.
10.1038/ncomms3384
PubMed Web of Science® Google Scholar
17Brufau G, Stellaard F, Prado K, et al. Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism. Hepatology. 2010; 52: 1455-1464.
10.1002/hep.23831
CAS PubMed Web of Science® Google Scholar
18Haeusler RA, Astiarraga B, Camastra S, Accili D, Ferrannini E. Human insulin resistance is associated with increased plasma levels of 12alpha-hydroxylated bile acids. Diabetes. 2013; 62: 4184-4191.
10.2337/db13-0639
CAS PubMed Web of Science® Google Scholar
19Wewalka M, Patti M, Barbato C, Houten SM, Goldfine AB. Fasting serum taurine-conjugated bile acids are elevated in type 2 diabetes and do not change with intensification of insulin. J Clin Endocrinol Metab. 2014; 99: 1442-1451.
10.1210/jc.2013-3367
CAS PubMed Web of Science® Google Scholar
20Ryan KK, Tremaroli V, Clemmensen C, et al. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature. 2014; 509: 183-188.
10.1038/nature13135
CAS PubMed Web of Science® Google Scholar
21Gu Y, Wang X, Li J, et al. Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment. Nat Commun. 2017; 8: 1785.
10.1038/s41467-017-01682-2
PubMed Web of Science® Google Scholar
22Liu R, Hong J, Xu X, et al. Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention. Nat Med. 2017; 23: 859-868.
10.1038/nm.4358
CAS PubMed Web of Science® Google Scholar
23Chavez-Talavera O, Tailleux A, Lefebvre P, Staels B. Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease. Gastroenterology. 2017; 152: 1679-1694.e3.
10.1053/j.gastro.2017.01.055
CAS PubMed Web of Science® Google Scholar
24Sonne DP, van Nierop FS, Kulik W, Soeters MR, Vilsbøll T, Knop FK. Postprandial plasma concentrations of individual bile acids and FGF-19 in patients with type 2 diabetes. J Clin Endocrinol Metab. 2016; 101: 3002-3009.
10.1210/jc.2016-1607
CAS PubMed Web of Science® Google Scholar
25Wu H, Esteve E, Tremaroli V, et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med. 2017; 23: 850-858.
10.1038/nm.4345
CAS PubMed Web of Science® Google Scholar
26Sun L, Xie C, Wang G, et al. Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. Nat Med. 2018; 24: 1919-1929.
10.1038/s41591-018-0222-4
CAS PubMed Web of Science® Google Scholar
27Albaugh VL, Flynn CR, Cai S, Xiao Y, Tamboli RA, Abumrad NN. Early increases in bile acids post Roux-en-Y gastric bypass are driven by insulin-sensitizing, secondary bile acids. J Clin Endocrinol Metab. 2015; 100: E1225-E1233.
10.1210/jc.2015-2467
PubMed Web of Science® Google Scholar
28Werling M, Vincent RP, Cross GF, et al. Enhanced fasting and post-prandial plasma bile acid responses after Roux-en-Y gastric bypass surgery. Scand J Gastroenterol. 2013; 48: 1257-1264.
10.3109/00365521.2013.833647
PubMed Web of Science® Google Scholar
29Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev. 2009; 89: 147-191.
10.1152/physrev.00010.2008
CAS PubMed Web of Science® Google Scholar
30Hylemon PB, Zhou H, Pandak WM, Ren S, Gil G, Dent P. Bile acids as regulatory molecules. J Lipid Res. 2009; 50: 1509-1520.
10.1194/jlr.R900007-JLR200
CAS PubMed Web of Science® Google Scholar
31Thomas C, Gioiello A, Noriega L, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 2009; 10: 167-177.
10.1016/j.cmet.2009.08.001
CAS PubMed Web of Science® Google Scholar
32Teodoro JS, Zouhar P, Flachs P, et al. Enhancement of brown fat thermogenesis using chenodeoxycholic acid in mice. Int J Obes (Lond). 2014; 38: 1027-1034.
10.1038/ijo.2013.230
CAS PubMed Web of Science® Google Scholar
33Ding L, Sousa KM, Jin L, et al. Vertical sleeve gastrectomy activates GPBAR-1/TGR5 to sustain weight loss, improve fatty liver, and remit insulin resistance in mice. Hepatology. 2016; 64: 760-773.
10.1002/hep.28689
CAS PubMed Web of Science® Google Scholar
34Vassileva G, Golovko A, Markowitz L, et al. Targeted deletion of Gpbar1 protects mice from cholesterol gallstone formation. Biochem J. 2006; 398: 423-430.
10.1042/BJ20060537
CAS PubMed Web of Science® Google Scholar
35Vitek L, Haluzik M. The role of bile acids in metabolic regulation. J Endocrinol. 2016; 228: R85-R96.
10.1530/JOE-15-0469
CAS PubMed Web of Science® Google Scholar
36Watanabe M, Houten SM, Mataki C, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature. 2006; 439: 484-489.
10.1038/nature04330
CAS PubMed Web of Science® Google Scholar
37Maruyama T, Miyamoto Y, Nakamura T, et al. Identification of membrane-type receptor for bile acids (M-BAR). Biochem Biophys Res Commun. 2002; 298: 714-719.
10.1016/S0006-291X(02)02550-0
CAS PubMed Web of Science® Google Scholar
38Olivares M, Neyrinck AM, Potgens SA, et al. The DPP-4 inhibitor vildagliptin impacts the gut microbiota and prevents disruption of intestinal homeostasis induced by a Western diet in mice. Diabetologia. 2018; 61: 1838-1848.
10.1007/s00125-018-4647-6
CAS PubMed Web of Science® Google Scholar
39Gu W, Liang L, Wang S, et al.; for the SUNSHINE Study Group.Efficacy and safety of saxagliptin monotherapy or added to metformin in Chinese patients with type 2 diabetes mellitus: results from the 24-week, post-marketing SUNSHINE study. J Diabetes. 2016; 8: 809-815.
10.1111/1753-0407.12360
CAS PubMed Web of Science® Google Scholar
40Lv X, Zhou W, Sun J, et al. Visceral adiposity is significantly associated with type 2 diabetes in middle-aged and elderly Chinese women: a cross-sectional study. J Diabetes. 2017; 9: 920-928.
10.1111/1753-0407.12499
CAS PubMed Web of Science® Google Scholar
41Lackey DE, Olefsky JM. Regulation of metabolism by the innate immune system. Nat Rev Endocrinol. 2016; 12: 15-28.
10.1038/nrendo.2015.189
CAS PubMed Web of Science® Google Scholar
42Choi J, Joseph L, Pilote L. Obesity and C-reactive protein in various populations: a systematic review and meta-analysis. Obes Rev. 2013; 14: 232-244.
10.1111/obr.12003
CAS PubMed Web of Science® Google Scholar
43Poitou C, Coussieu C, Rouault C, et al. Serum amyloid A: a marker of adiposity-induced low-grade inflammation but not of metabolic status. Obesity (Silver Spring). 2006; 14: 309-318.
10.1038/oby.2006.40
CAS PubMed Web of Science® Google Scholar
44Bae EJ. DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control. Arch Pharm Res. 2016; 39: 1114-1128.
10.1007/s12272-016-0813-x
CAS PubMed Web of Science® Google Scholar
45Indulekha K, Anjana RM, Surendar J, Mohan V. Association of visceral and subcutaneous fat with glucose intolerance, insulin resistance, adipocytokines and inflammatory markers in Asian Indians (CURES-113). Clin Biochem. 2011; 44: 281-287.
10.1016/j.clinbiochem.2010.12.015
CAS PubMed Web of Science® Google Scholar
46Deeks ED. Deoxycholic acid: a review in submental fat contouring. Am J Clin Dermatol. 2016; 17: 701-707.
10.1007/s40257-016-0231-3
PubMed Web of Science® Google Scholar
47 WHO, IASO, IOTF. The Asia-Pacific Perspective: Redefining Obesity and its Treatment. Melbourne: International Diabetes Institute; 2000.
Google Scholar
48Zhang W, Chen Q, Yuan Z et al. A routine biomarker-based risk prediction model formetabolic syndrome in urban Han Chinese population. Bmc Public Health. 2015; 15: 64.
10.1186/s12889-015-1424-z
PubMed Web of Science® Google Scholar

Citing Literature

Volume11, Issue12

December 2019

Pages 982-992

This article also appears in:

Clinical Science

Saxagliptin alters bile acid profiles and yields metabolic benefits in drug-naïve overweight or obese type 2 diabetes patient^†

超重或肥胖的初治2型糖尿病患者服用沙格列汀后胆汁酸组分的改变及代谢获益

Abstract

Background

Methods

Results

Conclusions

摘要

背景

方法

结果

结论

Supporting Information

REFERENCES

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Saxagliptin alters bile acid profiles and yields metabolic benefits in drug-naïve overweight or obese type 2 diabetes patient†

超重或肥胖的初治2型糖尿病患者服用沙格列汀后胆汁酸组分的改变及代谢获益

Abstract

Background

Methods

Results

Conclusions

摘要

背景

方法

结果

结论

Supporting Information

REFERENCES

Citing Literature

References

Related

Information

Saxagliptin alters bile acid profiles and yields metabolic benefits in drug-naïve overweight or obese type 2 diabetes patient^†